Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
Open accessThe DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
PURPOSE: Trastuzumab (TZM) improves survival and the risk of recurrence among patients with early-stage HER2+ breast cancer (BC). TZM treatment can be given intravenously (IV-TZM) or subcutaneously (SC-TZM). Although both methods have similar efficacy and safety, they differ in dosage and administration. Previous studies of cost minimization determined that SC-TZM is associated with lower costs than IV-TZM; however, those studies did not include the costs associated with body weight-based dosage and the treatment of adverse drug reactions (ADRs). METHODS/PATIENTS: We performed a model-based cost-minimization analysis. The analysis included direct and indirect medical costs associated with TZM preparation (adjusted by body weight) and administration and also costs due to severe ADRs and non-medical costs that occurred during the total treatment course (18 cycles). We performed a sensitivity analysis to test the robustness of the results across various TZM costs and patient body weights. RESULTS: The overall cost (in USD) of IV-TZM treatment was $83,309.1 per patient compared with $77,067.7 per patient for SC-TZM. Thus, one year of SC-TZM treatment cost $6,241.4 less per patient than one year of IV-TZM treatment. The sensitivity analysis revealed that the results were mainly driven by the price of each TZM vial and body weight. CONCLUSION: SC-TZM is a cost-saving therapy for Chilean patients with early-stage HER2+ BC. Given their similar efficacy and safety, we suggest the use of SC formulations rather than IV formulations. The use of SC-TZM instead of IV-TZM may have a significant economic impact on public/private healthcare systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One publication reported the costs for management of adverse events, which were slightly higher for SC versus IV delivery (US$1574 vs. US$1715 for 18 cycles) [71].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566 · cited 1×
“Although left ventricular dysfunction is not considered a serious ADR, we included it in our analysis because it requires considerable economic interventions: at least two medical evaluations, two echocardiograms, and new loading doses upon restart of therapy after recovery of cardiac function [17].”
BackgroundCarlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Irwin, M. L., McTiernan, A., Baumgartner, R. N., Baumgartner, K. B., Bernstein, L., Gilliland, F. D., & Ballard-Barbash, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.036 · Cited by 360 · cited 1×
“That scenario might be unlikely, because a previous study showed that patients with BC tend to increase their body weight slightly during treatment [18].”
ResultIsmael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351 · cited 10×
“Given the equivalence in efficacy between SC-TZM and IV-TZM, we encourage the use of SC-TZM instead of IV-TZM for the treatment of patients with HER2+ early BC.”
BackgroundMethodInfluentialDahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., & Murray, S. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0001 · Cited by 231 · cited 1×
“The use of TZM in combination with chemotherapy (CT) in the treatment of early-stage HER2+ BC improves survival by up to 35% (with 1 year of TZM use) and reduces the risk of recurrence by 33–52%, including locoregional recurrence [1,4,5,7,8].”
MethodPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230 · cited 1×
“The cost of pharmaceutical formulations is a key factor when selecting and implementing a therapeutic intervention in any population, especially when there are alternatives with similar therapeutic efficacy [14].”
BackgroundWynne, C., Harvey, V. J., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012436560 · Cited by 130 · cited 15×
“Given the equivalence in efficacy between SC-TZM and IV-TZM, we encourage the use of SC-TZM instead of IV-TZM for the treatment of patients with HER2+ early BC.”
BackgroundMethodInfluentialDe Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine · doi:10.1002/cam4.573 · Cited by 112 · cited 1×
“determined that SC-TZM was associated with lower costs than IV-TZM, but the cost estimates in those studies only included the time patients spent in the treatment chairs and the active time spent by the healthcare personnel to provide the treatment [23,24].”
BackgroundJackisch, C., Hegg, R., Stroyakovskiy, D., Ahn, J., Melichar, B., Chen, S., Kim, S., Lichinitser, M., Starosławska, E., Kunz, G., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.087 · Cited by 83 · cited 1×
“The study concluded that SC-TZM is an effective alternative to IV-TZM and, given its simplicity and ease of use, might represent a cost-effective and time-saving choice for patients and medical staff [12,13].”
BackgroundBreast Cancer Clinical Practice Guidelines in Oncology
Carlson, R. W., Anderson, B. O., Burstein, H. J., Cox, C. E., Edge, S. B., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., Hayes, D. F., Hudis, C. A., et al. (2005) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2005.0015 · Cited by 77
Research works printed but not linked: 1
- MINSAL. Guías Clínicas AUGE Cáncer de Mama. MINSAL. 2015;3: 8–12. Available: https://www.minsal.cl/wp-content/uploads/2015/09/GPC-CaMama.pdf
Cited by
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology
Jacquot, G., Navarro, P. L., Grange, C., Boudali, L., Harlepp, S., Pivot, X. B., & Detappe, A. (2024) · Advanced Materials · doi:10.1002/adma.202406604 · Cited by 27
Palacios, A., Rojas‐Roque, C., González, L., Bardach, A., Ciapponi, A., Peckaitis, C., Pichón-Rivière, A., & Augustovski, F. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01014-9 · Cited by 25
Hsieh, P.-H., Kacew, A. J., Dreyer, M. S., Serritella, A. V., Knoebel, R. W., Strohbehn, G. W., & Ratain, M. J. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00393-2 · Cited by 22
Parra, A., Hernandez, C. A., & Prieto‐Pinto, L. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2249232 · Cited by 17
“Seven studies documented the cost of trastuzumab in its SC and IV presentations for treating patients with breast cancer [18,20,21,27–30].”
BackgroundMethodInfluential
Metadata
- Authors
- Rojas, L., Muñiz, S., Medina, L., Peña, J., Acevedo, F., Pinto, M. P., & Sanchez, C.
- Affiliations
- Pontificia Universidad Católica de Chile (CL)
- Complejo Asistencial Sótero del Río (CL)
- Corresponding author
- Sanchez, Cesar
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-02-05
- Volume
- 15
- Issue
- 2
- Pages
- e0227961
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7001963
- OpenAlex
- W3005440288
- Cited by
- 23
- References
- 22
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 2
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, early breast cancer, cost-minimization analysis, weight-based dosing, adverse drug reactions, drug costs, health care costs, Chilean patients
- MeSH terms
- Trastuzumab, Breast Neoplasms, Costs and Cost Analysis, Dose-Response Relationship, Drug, Female, Health Resources, Humans, Injections, Subcutaneous, Incidence, Health Care Costs, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0227961
- The paper
- Rojas, L., Muñiz, S., Medina, L., Peña, J., Acevedo, F., Pinto, M. P., & Sanchez, C. (2020). Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0227961
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
